PTGS2 and exocrine pancreatic carcinoma: In this respect, Chuang et al.69 demonstrated that COX-2 inhibition is not sufficient to explain the cytotoxic effect of celecoxib in pancreatic carcinoma and glioblastoma cell lines expressing variable levels of COX-2.